Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PPARG | P37231 | 3/20 | 0.42 |
| ▸ | MAOB | P27338 | 3/20 | 0.41 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.36 |
| ▸ | MAOA | P21397 | 1/20 | 0.36 |
| ▸ | TGM2 | P21980 | 1/20 | 0.36 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.36 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.36 |
| ▸ | PSMB11 | A5LHX3 | 1/20 | 0.36 |
| ▸ | PSMA7 | O14818 | 1/20 | 0.36 |
| ▸ | PSMB1 | P20618 | 1/20 | 0.36 |
| ▸ | PSMA1 | P25786 | 1/20 | 0.36 |
| ▸ | PSMA2 | P25787 | 1/20 | 0.36 |
| ▸ | PSMA3 | P25788 | 1/20 | 0.36 |
| ▸ | PSMA4 | P25789 | 1/20 | 0.36 |
| ▸ | PSMB8 | P28062 | 1/20 | 0.36 |
| ▸ | PSMB9 | P28065 | 1/20 | 0.36 |
| ▸ | PSMA5 | P28066 | 1/20 | 0.36 |
| ▸ | PSMB4 | P28070 | 1/20 | 0.36 |
| ▸ | PSMB6 | P28072 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18192797 | 0.87 | PPARG (0.41) | PPARGMAOBSMN1; SMN2TGM2MME | |
| SCHEMBL15486994 | 0.83 | ACP3 (0.45) | KDM4EALDH1A1TDP1PSMB5KMT2A | |
| SCHEMBL15720879 | 0.83 | ACP3 (0.45) | KDM4EALDH1A1TDP1PSMB5KMT2A | |
| SCHEMBL721545 | 0.78 | PPARG (0.40) | PPARGMAOBSMN1; SMN2TGM2KMT2A | |
| SCHEMBL721544 | 0.78 | PPARG (0.40) | PPARGMAOBSMN1; SMN2TGM2KMT2A | |
| SCHEMBL15720921 | 0.77 | CYP2D6 (0.46) | SMN1; SMN2KDM4EALDH1A1TDP1KMT2A | |
| SCHEMBL1028181 | 0.76 | BTN3A1 (0.40) | KDM4EALDH1A1KMT2AMEN1BTN3A1 | |
| SCHEMBL1786739 | 0.76 | BTN3A1 (0.41) | KDM4EALDH1A1KMT2ABTN3A1 | |
| SCHEMBL15487036 | 0.75 | ALDH1A1 (0.39) | KDM4EALDH1A1KMT2AMEN1BTN3A1 | |
| SCHEMBL723909 | 0.75 | PPARG (0.39) | PPARGMAOBSMN1; SMN2ALDH1A1SCN9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8759318-B2 | Phosphoramidate derivatives of guanosine nucleoside compounds for treatment of viral infections | INHIBITEX, INC. (US) | 2014-06-24 | — | — | US | disclosed |
| US-20120052046-A1 | Phosphoramidate Derivatives of Guanosine Nucleoside Compunds for Treatment of Viral Infections | UNIVERSITY COLLEGE CARDIFF CONSULTANTS LIMITED (GB) | 2012-03-01 | — | — | US | disclosed |
| EP-2385951-A2 | PHOSPHORAMIDATE DERIVATIVES OF GUANOSINE NUCLEOSIDE COMPOUNDS FOR TREATMENT OF VIRAL INFECTIONS | University College Cardiff Consultants, Ltd. (GB) | 2011-11-16 | — | — | EP | disclosed |
| US-20110254856-A1 | MOBILE TERMINAL AND METHOD OF CONTROLLING OPERATION OF THE MOBILE TERMINAL | LG ELECTRONICS INC. (KR) | 2011-10-20 | — | — | US | disclosed |
| WO-2010081082-A2 | PHOSPHORAMIDATE DERIVATIVES OF GUANOSINE NUCLEOSIDE COMPOUNDS FOR TREATMENT OF VIRAL INFECTIONS | UNIVERSITY COLLEGE OF CARDIFF CONSULTANTS LIMITED (GB) | 2010-07-15 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120052046-A1 | Phosphoramidate Derivatives of Guanosine Nucleoside Compunds for Treatment of Viral Infections | PNP, SAMHD1, MTAP | PPARG 1792/4885MAOB 3783/4885SMN1; SMN2 858/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.